Pharmacological interventions in traumatic brain injury: Can we rely on systematic reviews for evidence?

Injury

Volumn 47, Issue 3, 2016, Pages 516-524

  Gultekin, Riza ^a,b,c   Huang, Sean ^a   Clavisi, Ornella ^b   Pattuwage, Loyal ^b   König, Thomas C ^c   Gruen, Russell ^a,b  

^a ALFRED HEALTH   (Australia)

^b NATIONAL TRAUMA RESEARCH INSTITUTE   (Australia)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute brain injury; Evidence based medicine; Pharmacology; Systematic review; Trauma

Indexed keywords

ACUTE PHASE RESPONSE; CLINICAL EVALUATION; CLINICAL RESEARCH; HUMAN; INTERVENTION STUDY; NERVOUS SYSTEM INJURY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TRAUMATIC BRAIN INJURY; VALIDATION STUDY; BRAIN INJURIES, TRAUMATIC; EVIDENCE BASED MEDICINE; MEDICAL RESEARCH; PATHOPHYSIOLOGY; TRENDS;

ANTICONVULSIVE AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC SEDATIVE AGENT; PROGESTERONE;

ANTICONVULSANTS; BIOMEDICAL RESEARCH; BRAIN INJURIES, TRAUMATIC; DOPAMINE AGONISTS; EVIDENCE-BASED MEDICINE; HUMANS; HYPNOTICS AND SEDATIVES; PROGESTERONE;

EID: 84979469581     PISSN: 00201383     EISSN: 18790267     Source Type: Journal    
DOI: 10.1016/j.injury.2015.10.011     Document Type: Review

References (65)

1. Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann C, Manley GT, Gruen RL. Early management of severe traumatic brain injury. Lancet 2012;380: 1088-98.
2. Reilly PL. Current evaluation of TBI epidemiology in an ageing society with improved preventative measures. In: Morganti-Kossmann C, Raghupathi R, Maas A, editors. Traumatic brain and spinal cord injury: challenges and developments. Cambridge: Cambridge University Press; 2012.
3. Abelson-Mitchell N. Epidemiology and prevention of head injuries: literature review. J Clin Nurs 2008;17:46-57.
4. Maas AI, Stocchetti N, Bullock R. Modrate and severe traumatic brain injury in adults. Lancet Neurol 2008;7:728-41.
5. National Trauma Research Institute. EvidenceMap.org [Online]; 2014 [cited 2014 August 25. Available from: HYPERLINK ''http://evidencemap.org'' http://evidencemap.org.
6. Thurman DJ, Sniezek JE, Johnson D, Greenspan A, Smith SM. Guidelines for surveillance of central nervous system injury. Atlanta: CDC, US Department of Health and Human Services, Public Health Service; 1995.
7. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7(10).
8. Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev 2004;1.
9. Gravel J, D'Angelo A, Carriere B, Crevier L, Beauchamp MH, Chauny JM, et al. Interventions provided in the acute phase for mild traumatic brain injury: a systematic review. Syst Rev 2013;2(63).
10. Arango MF, Bainbridge D. Magnesium for acute traumatic brain injury. Cochrane Database Syst Rev 2008;(4).
11. Comper P, Bisschop SM, Carnide N, Tricco A. A systematic review of treatments for mild traumatic brain injury. Brain Inj 2005;19(11):863-80.
12. Frenette AJ, Kanji S, Rees L, Williamson DR, Perreault MM, Turgeon AF, et al. Efficacy and safety of dopamine agonists in traumatic brain injury: a system-atic review of randomized controlled trials. J Neurotrauma 2012;29(1):1-18.
13. Teasell R, Bayona N, Lippert C, Villamere J, Hellings C. Post-traumatic seizure disorder following acquired brain injury. Brain Inj 2007;21(2):201-14.
14. Roberts DJ, Hall RI, Kramer AH, Robertson HL, Gallagher CN, Zygun DA. Sedation for critically ill adults with severe traumatic brain injury: a sys-tematic review of randomized controlled trials. Crit Care Med 2011;39(12): 2743-51.
15. Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. Neurocrit Care 2014;21(1):163-73.
16. Ma J, Huang S, Qin S, You C. Progesterone for acute traumatic brain injury. Cochrane Database Syst Rev 2012;(10).
17. Lei J, Gao GY, Jiang JY. Is management of acute traumatic brain injury effective? A literature review of published Cochrane Systematic Reviews. Chin J Trau-matol 2012;15(1):17-22.
18. Gu JW, Yang T, Kuang YQ, Huang HD, Kong B, Shu HF, et al. Comparison of the safety and efficacy of propofol with midazolam for sedation of patients with severe traumatic brain injury: a meta-analysis. J Crit Care 2014;29(2):287-90.
19. Zafar SN, Khan AA, Ghauri AA, Shamim MS. Phenytoin versus Leviteracetam for seizure prophylaxis after brain injury-a meta analysis. BMC Neurol 2012;12(30).
20. Forsyth RJ, Jayamoni B, Paine TC. Monoaminergic agonists for acute traumatic brain injury. Cochrane Database Syst Rev 2006;(4).
21. Perel P, Roberts I, Shakur H, Thinkhamrop B, Phuenpathom N, Yutthakasem-sunt S. Haemostatic drugs for traumatic brain injury. Cochrane Database Syst Rev 2010;(1).
22. Robert I. Aminosteroids for acute traumatic brain injury. Cochrane Database Syst Rev 2010;(4).
23. Roberts I, Shakur H, Ker K, Coats T. CRASH-2 trial collaborators antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011;(1).
24. Schierhout G, Roberts I. Prophylactic antiepileptic agents after head injury: a systematic review. J Neurol Neurosurg Psychiatry 1998;64(1):108-12.
25. Lu J, Gary KW, Neimeier JP, Ward J, Lapane KL. Randomized controlled trials in adult traumatic brain injury. Brain Inj 2012;26(13-14).
26. Siddall OM. Use of methylphenidate in traumatic brain injury. Ann Pharmac-other 2005;39(7-8):1309-13.
27. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999;83(2):302-20.
28. Altura BM, Altura BT. Magnesium, electrolyte transport and coronary vascular tone. Drugs 1984;8(Suppl 1):120-42.
29. Dacey MJ. Hypomagnesemic disorders. Crit Care Clin 2001;17(1):155-73.
30. Kahraman S, Ozgurtas T, Kayali H, Atabey C, Kutluay T, Timurkaynak E. Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results. Clin Chim Acta; Int J Clin Chem 2003;334(1-2):211-5.
31. Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. Hypomagneemia and hypophosphatemia at admission in patients with severe head injury. Crit Care Med 2000;28(6):2022-5.
32. Vink R, McIntosh TK, Demediuk P, Weiner MW, Faden AI. Decline in intracel-lular free Mg2+ is associated with irreversible tissue injury after brain trauma. J Biol Chem 1988;263(2):757-61.
33. Zhou GS, Zhao HY, Zhu XL. Effect of large dose of magnesium sulfate on patients with brain injury. Chin J Traumatol 2001;17(3):161-2.
34. Zhou GS, Ma XQ, Zhou MK. Neuroprotective effect of magnesium on patients with brain traum. Zhongguo Linchuang Kangfu 2004;8(7):1356-7.
35. Feeney DM. From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. In: Freund HJ, Sabel BA, Witte OW, editors. Advances in neurology. Philadelphia: Advances in Neurology; 1997. p. 383-94.
36. Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci 2000;27(2):97-105.
37. Goldstein LB. Effects of amphetamines and small related molecules on recov-ery after stroke in animals and man. Neuropharmacology 2000;39(5):852-9.
38. Sutton RL, Hovda DA, Chen MJ, Feeney DM. Alleviation of brain injury-induced cerebral metabolic depression by amphetamine: a cytochrome oxidase histo-chemistry study. Neural Plasticity 2000;7(1-2):109-25.
39. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 1988;23(1):94-7.
40. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke further evi-dence. Stroke 1995;26(12):2254-9.
41. Butefisch CM, Davis BC, Sawaki L, Wadvogel D, Classen J, Kopylev L. Modulation of use-dependent plasticity by D-amphetamine. Ann Neurol 2002;51(1):59-68.
42. Holcomb JB. Methods for improved hemorrhage control. Crit Care 2004;8(Suppl 2):57-60.
43. Mannucci PM, Levi M. Prevention and treatment of major blood loss. New Engl J Med 2007;356(22):2301-11.
44. Astrup J. ''Ultra-early'' antifibrinolytic treatment of subarachnoidal bleeding with tranexamic acid. Ugeskrift for Laeger 2006;168(11):1107-11.
45. Dewan Y, Komolafe EO, Mejía-Mantilla JH, Perel P, Roberts I, Shakur H. CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-con-trolled trial. Trials 2012;13:87.
46. Demopoulos HB, Selignman ML, Seligman ML. Further studies on free radical pathology in the major central nervous system disorders: effects of very high doses of methylprednisolone on the functional outcome, morphology, and chemistry of experimental spinal cord impact injury. Can J Physiol Pharmacol 1982;60:1415-24.
47. Hall ED, Yonkers PA, McCall JM, Braughler JM. Effects of the 21 aminosteroid U-74006F on experimental head injury in mice. J Neurosurg 1988;68(3):456-61.
48. Bleck T. Tirilazad mesylate in the treatment of head injury. Ongoing trial.
49. Hickenbottom MD, Grotta J. Neuroprotective therapy. Semin Neurol 1998;18(4):485-92.
50. Gentile NT, McIntosh TK. Antagonists of excitatory amino acids and endoge-nous opioid peptides in the treatment of experimental central nervous system injury. Ann Emerg Med 1993;22(6):1028-34.
51. Duhaime AC. Exciting your neurons to death: can we prevent cell loss after brain injury? Pediat Neurosurg 1994;21(2):117-23.
52. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26(3):503-13.
53. Schumacher M, Robel P, Baulieu EE. Development and regeneration of the nervous system: a role for neurosteroids. Dev Neurosci 1996;18:6-21.
54. Chen J, Chopp M, Li Y. Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rats. J Neurol Sci 1999;171:24-30.
55. Asbury ET, Fritts ME, Horton JE, Isaac WL. Progesterone facilitates the acqui-sition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat. Behav Brain Res 1998;97:99-106.
56. Cervantes M, Gonzalez-Vidal MD, Ruelas R, Escobar A, Morali G. Neuro-protective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus. Arch Med Res 2002;33:6-14.
57. Roof RL, Duvdevani R, Stein DG. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Restorative Neurol Neurosci 1992;4:425-7.
58. Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxida-tion following traumatic brain injury in rats. Mol Chem Neuropathol 1997;31:1-11.
59. Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002;178(1):59-67.
60. Gibson CL, Gray LJ. Progesterone for treatment of experimental brain injury: a systematic review. Brain 2008;131(Pt 2):318-28.
61. Klimek M, Dammers R. Antiepileptic drug therapy in the perioperative course of neurosurgical patients. Curr Opin Anaesthesiol 2010;23(5):564-7.
62. Urwin SC, Menon DK. Comparative tolerability of sedative agents in head-injured adults. Drug Saf 2004;27:107-33.
63. Flower O, Hellings S. Sedation in traumatic brain injury. Emerg Med Int 2012.
64. Wyte SR, Shapiro HM, Turner P, Harris AB. Ketamine-induced intracranial hypertension. Anesthesiology 1972;36(2):1200-4.
65. Shapiro HM, Wyte SR, Harris AB. Ketamine anesthesia in patients with intracranial pathology. Br J Anaesth 1972;44:1200-4.